Qiming Venture Partners Weekly: Top 10 Portfolio News Vol. 33, Oct. 28, 2026
Celebrating milestone moments with Qiming Venture Partners portfolio companies
Editor's Note: In 2026, the Qiming Weekly has been upgraded and refreshed, with regular weekly updates featuring only ten major developments from Qiming Venture Partners portfolio companies, covering funding progress and breakthroughs. In the wave of technology and innovation, every step entrepreneurs take is worth recording. Qiming Venture Partners will continue to accelerate and empower entrepreneurs, and we look forward to following these milestone moments with you.
Major Partnerships
01/
Shengshu Technology's Vidu Provides Chief Technical Support for China's First AI Hyper-Realistic Theatrical Film
Recently, Qiming Venture Partners portfolio company Shengshu Technology announced that Sanxingdui: Future Past, a 100-minute sci-fi film produced by Bona Film Group, officially hit theaters on October 23, with Shengshu Technology's video generation model Vidu serving as the film's chief technical support. This is China's first AI hyper-realistic theatrical film to receive a public screening license from the National Film Administration. All characters in the film are AI-generated — there are no live actors, nor digital replicas of real actors.
In production, Bona Film Group's self-developed AIGMS Boka Cloud Studio collaborated with the Vidu video model to complete the full pipeline from storyboarding to image generation to video production, establishing a foundational architecture for AI-driven industrial filmmaking. Rather than pursuing photorealism alone, Vidu emphasizes cinematic expressiveness: whether characters can convey emotion, whether movements carry dramatic tension, and whether shots achieve narrative rhythm — these remain the model's continued focus. Previously, Vidu was the first to launch multi-subject reference video generation capabilities, achieving multiple industry-firsts in character consistency, complex dynamics, and camera controllability. This theatrical release marks AI video generation technology's leap from short clips to complete, controllable long-form cinematic storytelling.
02/
Tigermed Signs Strategic Cooperation Agreement with Fudan University School of Pharmacy and Quzhou Fudan Research Institute
Recently, Qiming Venture Partners portfolio company and integrated biomedical R&D services platform Tigermed (300347.SZ, 03347.HK) announced that on October 17, in celebration of the 90th anniversary of Fudan University School of Pharmacy, the company signed a strategic cooperation framework agreement with Fudan University School of Pharmacy and Quzhou Fudan Biomedical Innovation Research Institute (hereinafter "Quzhou Fudan Research Institute") at Fudan University's Zhangjiang campus. The three parties will deepen cooperation in innovative drug R&D, scientific research platform construction, regulatory filing and clinical development, investment incubation, and talent cultivation, jointly exploring new pathways for synergistic collaboration in innovative drug development and technology commercialization.
Under the agreement, Fudan University School of Pharmacy will leverage its strengths in scientific innovation and talent cultivation; the Quzhou Fudan Research Institute will provide project hosting and commercialization support through its research platforms and local resources; and Tigermed will contribute its expertise in regulatory filing, clinical development, and industrial resource coordination. The three parties will combine Frontage Laboratories' capabilities in preclinical research to provide druggability assessment, pharmacology and efficacy, pharmacokinetics, safety, and pharmaceutical research support for key innovative drug projects, and will explore establishing joint laboratories or research centers. Tigermed will also coordinate industrial resources to conduct project evaluation, financing, and industry matchmaking with all parties, accelerating the translation of research outcomes into clinical applications.
03/
DeepWay and Shell Deepen Global New Energy Heavy-Duty Truck Cooperation
Recently, Qiming Venture Partners portfolio company DeepWay announced that Shell Group Executive Vice President and Global Lubricants President Huang Zhichang, along with Shell Group Executive Vice President and Shell China Group Chair Qu Xuemei, visited DeepWay's Beijing office for discussions with DeepWay Co-founder and Chief Engineer Tan Changyu and the company's management and technical teams. The two sides conducted in-depth discussions on new energy heavy-duty truck technology innovation, charging and maintenance services, and global market cooperation. Their collaboration began with e-axle lubricant fluid matching: starting in 2025, DeepWay's self-developed e-axles have been equipped with Shell's professional lubricant products, and the two parties are currently advancing joint technical validation and development of next-generation e-axle fluid solutions.
During these discussions, the two sides identified three priority cooperation directions: first, collaborative R&D on technology, conducting joint development of e-axle-specific lubricant solutions targeting the core needs of lubrication and thermal management for new energy heavy-duty trucks; second, overseas market coordination, with focused discussion on pathways for European market entry, jointly building one-stop service solutions encompassing vehicle charging/swapping and routine maintenance to support DeepWay's intelligent heavy-duty trucks going global; and third, brand and market synergy, integrating both parties' industry resources and customer networks to reach global trunk logistics customers and jointly promote new energy intelligent heavy-duty truck solutions.
Product Releases
01/
Insta360's Antigravity Brand Launches Classic Remote Controller and 4G Video Transmission Enhancement Module
Recently, Qiming Venture Partners portfolio company Insta360 (688775.SH) announced that its incubated aerial photography brand Antigravity has launched two new accessories for its 8K panoramic drone Antigravity A1: a classic remote controller and a 4G video transmission enhancement module, further expanding aerial creation possibilities. The classic remote controller features a new dual-joystick design with refined damping feel and precise, smooth control response, enabling cinematic shots including orbiting tracking, push-in ascents, and dive transitions with ease. When paired with Vision FPV goggles, it adds fixed-view and free-view modes, balancing precise camera control with immersive exploration.
The 4G video transmission enhancement module automatically supplements connectivity via cellular network when native video transmission is obstructed or interfered with, providing connection assurance for flights between urban high-rises, over mountains, along coastlines, and in other long-distance and complex environments. The module has built-in eSIM, requiring no additional physical SIM card for activation, and includes 5GB of data and first-year service fee with initial activation, with coverage extending to European travel. Additionally, Antigravity has launched a Vision FPV goggles-dedicated 4G video transmission enhancement module that can independently connect to 4G networks, reducing interference from incoming calls and network fluctuations for more seamless immersive flight.
02/
Infinigence AI Jointly Releases Embodied Intelligence Reinforcement Learning Open-Source Framework RLinf v0.4
Recently, Qiming Venture Partners portfolio company and AI-native infrastructure company Infinigence AI announced the official release of RLinf v0.4, the world's first large-scale reinforcement learning training open-source framework for embodied intelligence, jointly developed with Tsinghua University, Beijing Zhongguancun Academy, and other institutions. The new version focuses on reinforcement learning needs in real physical scenarios, with systematic upgrades across four directions: "LEGO-style real robot systems, high-efficiency real robot algorithms, full-modality model support, and domestic computing infrastructure." It abstracts robotic arms, dexterous hands, cameras, mobile bases, and other hardware into plug-and-play modules, with upper-layer task and policy code requiring no changes when swapping bodies or configurations. New real-robot algorithms include online policy distillation and asynchronous real-time control, with online policy distillation requiring only 30 training steps to improve model task success rates from 67% to over 96%, and asynchronous real-time control compressing inference waiting time to approximately 2 milliseconds. The framework also integrates five cutting-edge world action models and VLA models including NVIDIA Cosmos3.
For computing adaptation, RLinf v0.4 adds support for Kunlun Core, Biren Technology (06082.HK), MetaX, and Intel XPU, and can now run seamlessly on NVIDIA, AMD, and six major domestic and heterogeneous accelerators. On Huawei Ascend platforms, end-to-end computing efficiency for 10 mainstream embodied models reaches over 75% of A100 performance. In ecosystem and academic terms, RLinf has been officially admitted to the PyTorch ecosystem and become the officially integrated reinforcement learning training engine for NVIDIA Isaac Lab v3.0. Two research results from the team were accepted to the top robotics learning conference CoRL 2026, and another paper was accepted to the top networking and systems conference NSDI 2027.
03/
Sharpa Releases Fingertip Tactile-Enabled Real Robot Dexterous Hand Manipulation Dataset SharpaDex v1.0
Recently, Qiming Venture Partners portfolio company and embodied intelligence company Sharpa officially released SharpaDex v1.0. This fingertip tactile-enabled real robot dexterous hand manipulation dataset sets a new scale record among publicly available datasets of its kind, and is now openly accessible on Hugging Face. The dataset contains approximately 300 hours of real robot manipulation data, encompassing 28,993 demonstrations, 59 tasks, and over 32.39 million frames. Data was collected by a dual-arm robot paired with dual Sharpa Wave (W01) dexterous hands, with each frame synchronously recording tactile information from 10 fingertips, multi-view vision, joint states, and action information, along with task descriptions and fine-grained language annotations.
The core feature of SharpaDex v1.0 is that tactile data comes from genuine, effective physical interaction: in approximately 64.9% of data frames, at least one finger is in contact, corresponding to roughly 195 hours of manipulation time, with over 418,000 fingertip contact events identified; approximately 18.3% of frames record both hands simultaneously contacting objects. Tasks cover flexible object manipulation, tool use, precision insertion, screwing, and granular material manipulation, among other scenarios, such as ironing clothes, prying nails, pipette liquid transfer, and battery installation, with approximately 83% of duration coming from complex dexterous manipulation tasks. The dataset also constructs a three-tier language annotation system of "task—subtask—atomic action," providing a data foundation for research in tactile representation learning, visuo-tactile fusion, and dexterous manipulation policy learning.
Technology Strength
WeRide's Physical AI Flywheel Selected as One of "Top 10 Automotive AI Application Cases of 2026"
Recently, Qiming Venture Partners portfolio company and global leading autonomous driving technology company WeRide (NASDAQ: WRD, 00800.HK) announced that its dual-model-driven physical AI flywheel has been selected as one of the "2026 Top 10 Automotive AI Application Cases" released by the World Intelligent Connected Vehicles Conference (WICV). In WeRide's physical AI flywheel, the world model WeRide GENESIS and the physical AI cognitive foundation model WeRide WITT collaborate: WITT extracts and validates physical facts from real-world road data, and GENESIS generates high-fidelity simulation scenes consistent with physical laws accordingly, intensifying training for complex road conditions and long-tail scenarios to improve R&D efficiency and complex scenario adaptability.
During the conference, WeRide Founder and CEO Dr. Tony Han delivered a keynote speech titled "The Critical Leap for Large-Scale Commercialization of Autonomous Driving" at the key technologies forum, sharing practices in empowering L2 assisted driving with L4 technology, and proposing that assisted driving solutions should be evaluated by "intelligence density" — how much intelligence each TOPS can produce. WeRide also deployed over ten Robotaxis and Robobuses for experience testing and shuttle services, with the Robotaxi experience route covering nearly 7 kilometers. Currently, the company has achieved full-stack commercialization from L2 to L4, with operations covering over 60 cities in 13 countries globally, an L4 autonomous driving fleet of approximately 3,600 vehicles, and its L2++ one-stage end-to-end assisted driving solution WRD 3.0 has accumulated mass production designations for over 30 vehicle models.
R&D Progress
01/
Microtide Biotechnology's In Vivo CAR-T Therapy GT801 Receives FDA Orphan Drug Designation
Recently, Qiming Venture Partners portfolio company Microtide Biotechnology announced that GT801, the core pipeline product of its in vivo CAR-T platform, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of autoimmune hemolytic anemia (AIHA). GT801 is an investigational in vivo CAR-T product based on mRNA and T cell-targeting lipid nanoparticle (LNP) delivery technology, which generates CAR-T cells capable of recognizing and eliminating CD19-positive B cells directly in the patient's body by delivering mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to the patient's T cells.
At the 2026 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, GT801 disclosed preliminary clinical study results in autoimmune disease patients via poster presentation: both AIHA patients treated with GT801 achieved complete remission (CR), with sustained peripheral B cell depletion and improvements in hemoglobin levels and other indicators observed. Under FDA regulations, products receiving orphan drug designation may qualify for clinical trial tax credits, waived user fees for marketing applications, and other incentives, with the opportunity to receive seven years of market exclusivity upon approval. This designation provides important policy support for GT801's international development targeting autoimmune diseases.
02/
Insight Lifetech's IVUS System Approved for Sale in South Korea
Recently, Qiming Venture Partners portfolio company Insight Lifetech (688712.SH) announced that its intravascular ultrasound (IVUS) system has been approved for sale in South Korea. South Korea is one of the world's top ten medical device markets, with substantial market size and a highly open, innovation-embracing regulatory environment. This approval signifies that Insight Lifetech's IVUS product performance and quality have passed the standards of South Korea's demanding medical market, further completing the company's market access map in the Asia-Pacific region and offering local physicians and patients more high-quality, affordable precision diagnostic and treatment options.
Insight Lifetech's IVUS is China's first independently innovated 60MHz high-speed domestic IVUS product approved by the National Medical Products Administration (NMPA), and also the first Chinese IVUS system to receive EU certification. It features 40/60MHz imaging resolution and 100FPS imaging speed, and is equipped with the inSmartVision intelligent image analysis platform and EasyGo angiography co-registration function, helping physicians more rapidly identify lesions, optimize stent strategies, and improve procedural efficiency. Currently, Insight Lifetech products have entered over 2,500 hospitals in more than 60 countries and regions globally; in the first half of 2026, the company obtained 15 first-time international registration approvals and 11 international change registrations or filings.
03/
Adagene Announces Positive Topline Data from China Phase II Clinical Trial of LP-005 for PNH
Recently, Qiming Venture Partners portfolio company Adagene (01779.HK) announced positive topline data from its China Phase II clinical trial of LP-005, a self-developed dual-function antibody fusion protein, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). LP-005 simultaneously targets C3b and C5 in the proximal and terminal complement cascade, inhibiting all three complement pathways — classical, alternative, and lectin — with a longer half-life than existing therapies, enabling once-every-four-weeks intravenous administration. It is the first product from Adagene's dual-function antibody platform.
This multicenter, randomized, open-label Phase II trial enrolled 30 PNH patients across three dose cohorts: 900mg, 1200mg, and 1500mg. Data showed that at Week 12, lactate dehydrogenase (LDH) decreased significantly from baseline across all dose cohorts, with hemolysis control rates of 100% in both the 1200mg and 1500mg cohorts, transfusion independence achieved in all three cohorts, and no breakthrough hemolysis observed. At Week 24, 85.7% of patients in the 1500mg cohort achieved hemoglobin increase ≥2 g/dL while remaining transfusion-independent. No treatment-related serious adverse events were reported during the study, with overall good safety and tolerability. These results support further clinical development of LP-005.
Past Issues
Qiming Weekly | Top 10 Qiming Venture Partners Portfolio Company Developments Vol. 32, 2026.10.21
Qiming Honors | UBTECH, Biren Technology Named to 2026 Wealth Global Future 120
Qiming Venture Partners was founded in 2006. Currently, the firm manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, Qiming Venture Partners has focused on investing in outstanding early- and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have listed on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through mergers and acquisitions, with over 80 recognized as unicorns or super-unicorns in their respective industries.
Many Qiming Venture Partners portfolio companies have grown into the most influential companies in their fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ: HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ: WRD, 00800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Zhipu AI (02513.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), APT Medical (688617.SH), Sanyou Medical (688085.SH), AmoyDx (300685.SZ), Sinocelltech (688520.SH), Insilico Medicine (03696.HK), AusperBio, Yuanxin Technology, MediLink Therapeutics, Leads Biolabs, StepFun, and others.